Scott Galovan's most recent trade in Avanos Medical Inc was a trade of 4,228 Common Stock done at an average price of $24.6 . Disclosure was reported to the exchange on April 22, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avanos Medical Inc | Scott Galovan | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.64 per share. | 22 Apr 2026 | 4,228 | 135,596 (0%) | 0% | 24.6 | 104,178 | Common Stock |
| Avanos Medical Inc | Scott Galovan | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2026 | 70,115 | 96,697 | - | - | Employee Stock Option (right to buy) | |
| Avanos Medical Inc | Scott Galovan | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2026 | 69,630 | 96,212 | - | - | Employee Stock Option (right to buy) | |
| Avanos Medical Inc | Scott Galovan | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2026 | 69,630 | 96,212 | - | - | Employee Stock Option (right to buy) | |
| Avanos Medical Inc | Scott Galovan | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2026 | 29,481 | 139,824 (0%) | 0% | 0 | Common Stock | |
| Avanos Medical Inc | Scott Galovan | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2026 | 29,481 | 139,824 (0%) | 0% | 0 | Common Stock | |
| Avanos Medical Inc | Scott Galovan | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2026 | 29,481 | 139,824 (0%) | 0% | 0 | Common Stock | |
| Avanos Medical Inc | Scott Galovan | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.29 per share. | 09 Mar 2026 | 1,119 | 110,343 (0%) | 0% | 13.3 | 14,872 | Common Stock |
| Avanos Medical Inc | Scott Galovan | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.79 per share. | 06 Mar 2026 | 5,907 | 116,916 (0%) | 0% | 13.8 | 81,458 | Common Stock |
| Avanos Medical Inc | Scott Galovan | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.79 per share. | 06 Mar 2026 | 2,356 | 114,560 (0%) | 0% | 13.8 | 32,489 | Common Stock |
| Avanos Medical Inc | Scott Galovan | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.79 per share. | 06 Mar 2026 | 2,041 | 111,462 (0%) | 0% | 13.8 | 28,145 | Common Stock |
| Avanos Medical Inc | Scott Galovan | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.79 per share. | 06 Mar 2026 | 1,057 | 113,503 (0%) | 0% | 13.8 | 14,576 | Common Stock |